Recent regulatory filings have provided a clear window into the shifting ownership structure of Camp4 Therapeutics Corp (Nasdaq: CAMP4). According to an amended Schedule 13G filed on November 16, 2026, a significant partnership and its affiliates have adjusted their position in the company, now maintaining an ownership stake of just under ten percent of the total common shares outstanding.
The filing, submitted in strict accordance with SEC regulations, clarifies that the current holding remains below the critical thresholds that would necessitate a change-of-control disclosure. While the amendment confirms the specific scale of this institutional interest based on the most recent quarterly share count, it does not signal any immediate shift in corporate governance or control.
For observers tracking the company’s market position, this update arrives amidst a period of notable price volatility. Camp4 Therapeutics Corp has seen its share price fluctuate significantly over the past year, reaching a 52-week high of $7.75 in March 2026 before retreating to a low of $2.90 in July 2026. As of the market close on November 16, 2026, the stock was trading at $4.00, with a market capitalization of approximately $242.23 million.
While the amendment serves as a routine compliance measure regarding ownership thresholds, the consolidation of a nearly ten percent stake by a single partnership underscores the ongoing institutional scrutiny surrounding the company. At this stage, no further material corporate events or financial developments have been disclosed, leaving the market to weigh this ownership stability against the company’s broader healthcare sector trajectory.




